Biomedical Engineering Reference
In-Depth Information
Dahan E, Mendelson H (2001) An extreme-value model of concept testing. Manag Sci
47(1):102-116
Davis CR (2002) Calculated risk: a framework for evaluating product development. Sloan Manage
Rev 43(4):71-77
Day GS (1990) Market driven strategy: processes for creating value. The Free Press, New York
Day GS (2007) Is it real? Can we win? Is it worth doing? Harv Bus Rev 85(12):110-120
Devinney TM, Stewart DW (1988) Rethinking the product portfolio: a generalized investment
model. Manag Sci 34(9):1080-1095
Devinney TM, Stewart DW, Shocker AD (1985) A note on the application of portfolio theory: a
comment on Cardozo and Smith. J Mark 49(4):107-112
Dickison MW, Thornton AC, Graves S (2001) Technology portfolio management: optimizing
interdependent projects over multiple time periods. IEEE Trans Engineering Management
48(4):518-527
DiMasi JA (2000) New drug innovation and pharmaceutical industry structure: trends in the output
of pharmaceutical firms. Drug Inform J 34:1169-1194
DiMasi JA, Grabowski HG (2007) The cost of biopharmaceutical R&D: is biotech different?
Manag Decis Econ 28:469-479
DiMasi JA, Hansen RW, Grabowski HG, Lasagna L (1991) Cost of innovation in the pharmaceuti-
cal industry. J Heal Econ 10(2):107-142
DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug
development costs. J Heal Econ 22(2):151-185
Ding M, Eliashberg J (2002) Structuring the new product development pipeline. Manag Sci
48(3):343-363
Dvir D, Sadeh A, Malach-Pines A (2006) Projects and project managers: the relationship between
project managers' personality, project types, and project success. Proj Manag J 37(5):36-49
Elting LS, Martin CG, Cantor SB, Rubenstein EB (1999) Influence of data display formats on
physician investigators' decisions to stop clinical trials: prospective trial with repeated
measures. BMJ 318:1527-1531
Ernst H, Vitt J (2000) The influence of corporate acquisitions on the behaviour of key inventors.
R&D Management 30(2):105-120
Fama EF, Miller MH (1972) Theory of finance. Dryden Press, Hinsdale, IL
Faulkner TW (1996) Applying 'options thinking' to R&D valuation. Res Tech Manag 39(3):50-56
Fox GE, Baker NR, Bryant JL (1984) Economic models for R and D project selection in the pres-
ence of project interactions. Manag Sci 30(7):890-902
Garnier J-P (2008) Rebuilding the R&D engine in big pharma. Harv Bus Rev 86(5):68-76
Gear TE, Cowie GC (1980) A note on modeling project interdependence in research and develop-
ment. Decis Sci 11(4):738-748
Girotra K, Terwiesch C, Ulrich KT (2007) Valuing R&D projects in a portfolio: evidence from the
pharmaceutical industry. Manag Sci 53(9):1452-1466
Gittins JC (1979) Bandit processes and dynamic allocation indices. J R Stat Soc Ser B
41(2):148-177
GlaxoSmithKline (2011a) Our history. http://www.gsk.com/about/history.htm. Accessed Sept
2011
GlaxoSmithKline (2011b) Product development portfolio of GlaxoSmithKline. http://www.gsk.
com/investors/product_pipeline/docs/gsk-pipeline-2011.pdf. Accessed Sept 2011
Goettler R, Gordon BR (2011) Does AMD spur Intel to innovate more? Working Paper
Grabowski H, Vernon J (1990) A new look at the returns and risks to pharmaceutical R&D. Manag
Sci 36(7):804-821
Grabowski HG, Vernon JM (1994) Returns to R&D on new drug introductions in the 1980s. J Heal
Econ 13(4):383-406
Grabowski H, Vernon J, DiMasi J (2002) Returns on research and development for 1990s new drug
introductions. Pharmacoeconomics 20(Supplement 3):11-29
Grewal R, Chakravarty A, Ding M, Liechty J (2008) Counting chickens before the eggs hatch:
associating new product development portfolios with shareholder expectations in the pharma-
ceutical sector. Int J Res Mark 25(4):261-272
Search WWH ::
Custom Search